Stocktoria
Concord Medical Services Holdings Ltd CCM
Concord Medical Services Holdings Ltd (CCM) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend (safety: no dividend). FY2025 revenue was $65.9M at a -20.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.93 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.155 |
| Retained earnings / assets | -0.682 |
| EBIT / assets | -0.04 |
| Equity / liabilities | -0.448 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CCM | Concord Medical Services Holdings Ltd | 6/9 | -3.98 | — | +25.2% |
| AIRS | Airsculpt Technologies, Inc. | 3/9 | -0.63 | — | -15.8% |
| SBC | SBC Medical Group Holdings Inc | 3/9 | 8.55 | 6.7 | -15.5% |
| LFMD | LifeMD, Inc. | 5/9 | -9.85 | 13.9 | +25.3% |
| TOI | Oncology Institute, Inc. | 4/9 | -5.27 | — | +27.8% |
| HIMS | Hims & Hers Health, Inc. | 4/9 | 1.61 | 61.2 | +59% |
| TDOC | Teladoc Health, Inc. | 5/9 | -16.73 | — | -1.5% |
About Concord Medical Services Holdings Ltd
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
FAQ
Is CCM financially healthy?
Concord Medical Services Holdings Ltd's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CCM pay a dividend, and is it safe?
Yes. Concord Medical Services Holdings Ltd pays a dividend with a None payout ratio, rated “no dividend” for safety.
How profitable is CCM?
In FY2025, Concord Medical Services Holdings Ltd had a net margin of -20.2%.
Is CCM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Concord Medical Services Holdings Ltd: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.